Skip to content

Study on the effects and mechanisms of Jia Wei Yin Chen Hao Tang in the treatment of hypercholanemia during pregnancy

Study on the effects and mechanisms of Jia Wei Yin Chen Hao Tang in the treatment of hypercholanemia during pregnancy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400088564
Enrollment
Unknown
Registered
2024-08-21
Start date
2024-06-27
Completion date
Unknown
Last updated
2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholeacidemia during pregnancy

Interventions

(First stage) Modified Yin Chen Hao Tang+Ursodeoxycholic Acid Group:Take modified Yin Chen Hao Tang on the basis of ursodeoxycholic acid (250mg, oral, 2/day). The same goes for the modified Yin Chen H
(First stage) Modified Yin Chen Hao Tang+Ursodeoxycholic Acid Group:Administer 250mg of ursodeoxycholic acid orally, 2/day treatment until delivery
(Second stage) Simple flavored Yin Chen Hao Tang group:Basic formula of Jiawei Yinchenhao Tang, 1 dose/day of traditional Chinese medicine, taken twice in the morning and evening, for 2 weeks of treat
(Second stage) Modified Yin Chen Hao Tang+Ursodeoxycholic Acid Group:Take modified Yin Chen Hao Tang on the basis of ursodeoxycholic acid (250mg, oral, 2/day). The same goes for the modified Yin Chen
(Second stage) Simple ursodeoxycholic acid group:Administer 250mg of ursodeoxycholic acid orally, 2/day treatment until delivery

Sponsors

Department of Gynecology and Obstetrics Hospital Affiliated to Zhejiang University Medical College
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 46 Years

Inclusion criteria

Inclusion criteria: ? Single pregnant women who have undergone formal prenatal examination in our hospital and have a TBA>10mmol/L, with/without skin itching; ? The patient voluntarily accepts clinical observation and signs an informed consent form.

Exclusion criteria

Exclusion criteria: ? Patients with combined hepatitis or other infectious diseases; ? Concomitant cholelithiasis; ? Unwilling to accept clinical observation; ? Those who do not meet the inclusion criteria, do not use medication according to regulations, cannot determine the efficacy, or have incomplete information that affects the efficacy or safety judgment.

Design outcomes

Primary

MeasureTime frame
Maternal serological indicators;

Secondary

MeasureTime frame
Itching symptoms;Delivery outcome;Neonatal outcome;Pathological examination of the placenta;

Countries

China

Contacts

Public ContactBai Xiaoxia

Department of gynecology and obstetrics hospital affiliated to Zhejiang University Medical College

baixiaoxia@zju.edu.cn+86 139 5715 2365

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026